---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040171"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:05:23.490555+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransCode secures up to $20M flexible financing from Yorkville via SEPA and convertible notes

## Summary
- Up to $14M SEPA for common stock sales at 97% of lowest 3-day VWAP; up to $6M in pre-paid convertible notes at 5% discount.
- First $1M convertible note tranche expected upon filing Form 10-K; second $5M tranche after registration and shareholder approval.
- Convertible notes bear 5% interest, mature 18 months, convertible at 115% of prior day VWAP or 95% of lowest 7-day VWAP, floor at 20% of last trade.
- Company issued 29.89 Series A Preferred shares as PIK dividend to DEFJ and Tungsten from prior acquisition on April 6, 2026.
- CEO states financing extends runway into late 2027/early 2028, enabling completion of Phase 2a trial for TTX-MC138.

## SEC filing metadata
- accession: 0001104659-26-040171
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926040171/0001104659-26-040171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926040171/tm2611272d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040171
- JSON: https://secwatch.observer/filing/0001104659-26-040171.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040171.txt

## Source-grounded claims
- claim_id: 5c4e00054be33a4ecdf4bff54b7e2f728012c127
  claim: Transcode Therapeutics, Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD valued at $14 million (effective 2026-04-06).
  evidence_excerpt: On April 6, 2026 , TransCode Therapeutics, Inc., a Delaware corporation, (the “Company,” “we,” or “our”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited partnership (“Yorkville”), pursuant to which the Company has the right to sell to Yorkville up to $14 million of shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465926040171/0001104659-26-040171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.